BioSpace News Archive

Net sales amounted to SEK 96.8 million (54.9), corresponding to an increase of 76 percent in SEK and 57 percent adjusted for currency effects. Organic growth accounted for 35 percent and acquired growth for 22 percent.

BioInvent further strengthened its financial position in the third quarter through a directed share issue.

Takeda announced financial results for the first half of fiscal year 2022, upgrading reported and core forecasts and free cash flow outlook for the fiscal year and reconfirming Management Guidance for core growth at constant exchange rate.

Sales of SEK 798 (406) million, corresponding to an increase of 97% in SEK, whereof acquired growth 75% and currency effect 20%. Sales pro forma, adjusted for business related to Covid-19 tests, increased by 5% in local currencies.

MorphoSys AG announced that its licensing partner, GSK plc, provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis.

Gerresheimer AG and Merck KGaA, Darmstadt, Germany jointly developed a digital twin solution to further ensure traceability and trust in crucial steps along the pharmaceutical supply chain.

Kineta, Inc. announced that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting, to be held November 8-12, 2022 onsite in Boston, MA and online.

West Pharmaceutical Services, Inc. announced its financial results for the third-quarter 2022 and updated full-year 2022 financial guidance.

BIOLASE, Inc. announced that it will release third quarter 2022 financial and operating results on Thursday, November 10, 2022 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, November 7, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2022.